Ross’s story: An excerpt from “Life after Encephalitis” by Dr Ava Easton.
The Encephalitis Society
Dr Ava Easton
New Dementia interactive care pathway toolkit now available
Sarah Gillett, Managing Director, Neurology Academy
Sponsored Article
STADA Australia continues to innovate in Parkinson’s Disease with MOVAPO® pre-filled syringes (PFS) Parkinson’s Disease is a surprisingly prevalent condition with an estimated 10 million people worldwide and roughly 70,000 Australians (1 in every 340 people) suffering from the condition.1 It is the second most prevalent neurological condition exceeded only by dementia. It is more common…
Charcot-Marie-Tooth awareness film launches first ever video to highlight symptoms of neurological condition
For the first time in the UK, a short-film has been launched to raise awareness of the world’s most common inherited neurological condition Charcot-Marie-Tooth (CMT). It aims to spread the word about the condition because so few people have heard of it. Watch the film at http://cmt.org.uk/video/ The film has been backed by CMT expert and President…
ECTRIMS 2016
News highlights from ECTRIMS
Industry News
A neurology news update New data intelligence report analyses how people with neurological conditions in Wessex use hospital services and why A new Neurology Intelligence Report provides insight into how people with various neurological conditions can be better supported to stay well. The report is the work of NHiS in partnership with Wessex Strategic Clinical…
Dementia Conference calls for “earlier and more accurate diagnosis” of growing disease
Medical charity Cobalt held its inaugural annual Dementia Conference in conjunction with Siemens Healthcare, attracting over 100 healthcare professionals including radiologists, neurologists, psychiatrists, and nursing staff. “Dementia is now being recognised for what it is – a sizeable concern that places a significant drain on resources, stated Professor Iain Lyburn, Medical Director and research lead…
In Parkinson’s disease, patients may suffer from delayed ON as well as wearing OFF – which is more important?
Report from Britannia Pharmaceuticals on their plenary session on PD treatment, held at the 9th CONy Congress in Budapest, Hungary, March 2015
